Proudly Sponsored by: Abzena
SMi Group is thrilled to present the 7th annual conference, Biosimilars Europe, taking place on 29th & 30th September 2016 in Central London, UK. Gathering an audience of principle scientists and regulatory experts involved in biotechnology and compliance, Biosimilars Europe 2016 will provide a perfect platform to discuss global market developments and strategies to market access.
Created with a top panel of industry thought leaders, this year's event will capture expert insight by honing in on the biosimilar product life-cycle from early stage developments, protein characterization, and pricing & reimbursement; through to emerging markets and global developments.
Join us this autumn to arm yourself with the key requirements and tools for successful market entry through strategic direction on commercialization; insight into potential therapeutic areas; and guidance on product quality assessment (PQA) in biosimilar development.
OUR NOTABLE SPEAKER LINE-UP WILL INCLUDE:
- Huiguo Hu, General Manager of International Business, Shanghai CP Guojian Pharmaceutical Co Ltd
- Dr Niraj Chhaya, Risk Management, Boehringer Ingelheim GmbH
- Atanas Dimitrov, Head of Strategy & Portfolio Management, Merck Group
- Dr Alok Sharma, Head, Bio-Analytical Development, Lupin Ltd
- Dr Andrea Laslop, Head of Scientific Office, Austrian Agency for Health and Food Safety
- Joan O’Callaghan, Research Scientist for Regulatory Science Ireland, Health Products Regulatory Authority, Ireland
WHY YOU NEED TO BE THERE IN 2016:
- Hear how the evolving regulatory landscape and guidelines will impact on biosimilars
- Overcome market access and commercialization barriers
- Assess market trends and align your business strategy on emerging markets
- Technical updates on protein characterization and analytical comparability to speed up data collection
PREVIOUS ATTENDEE TESTIMONIALS:
"Really wide range of topics" - Kantar Health
"Rich in information and quality speakers" - Globyz Pharma
"Great discussions, networking and education" - Apobiologix
"Interesting mix of scientists, legal and commercial folk" - Allergan
"Impressive - beat my expectations" – Teva